Friday, Legend Biotech Corporation (NASDAQ:LEGN) and Johnson & Johnson (NYSE:JNJ) announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study.
Data shows that a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival (OS) for relapsed or lenalidomide-refractory multiple myeloma patients who have received at least one prior line of therapy.
The company says Carvykti is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as the second line.
These results were presented at the 2024 International Myeloma Society Annual Meeting.
The Phase 3 CARTITUDE-4 study evaluated Carvykti compared to standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) for relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy.
At a median follow-up of almost three years (34 months), median OS was not reached for ...
